| Description | The human antibody shows potent neutralization against authentic SARS-CoV-2 viruses, including variants of concern (VOCs). The mAb has high affinity with the apex of the RBD and exhibited potent SARS-CoV-2 neutralization against USA-WA1, Alpha, Beta, Gamma, and Delta VOCs. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (USA-WA1, Alpha, Beta, Gamma and Delta) |
| Epitope | Overlapping the binding sites of ACE2 to SARS-CoV-2 S protein. |
| Affinity | 21.8 nM |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | ELISA: The antibody started at 10 μg/mL with a serial 1:5 dilution. Bio-layer interferometry (BLI): The KD binding to SARS-CoV-2 RBD is 21.8 nM. Neutralization assay: the mAb neutralized each virus (USA-WA1, Alpha, and Beta, Gamma and Delta) potently with IC₅₀ values of 3.2, 5.5, 9.7, 3.7, and 1.5, and IC80 values of 10, 48, 49, 11.4, and 3.9 ng/mL, respectively. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
